Elanco, the animal health division of Eli Lilly & Company, has launched an enhanced business operation in Ireland.

The move follows the recent acquisition of Novartis Animal Health and Lohmann Animal Health.

Elanco has, traditionally, had a strong presence within the ruminant and pig industries, and its recent acquisitions, it says, will see its zone of influence will extend out to include the poultry sector while.

Speaking at the recent launch event, Elanco director Gaynor Hillier said that the company has a 60-year track record in delivering effective veterinary pharmaceutical solutions for veterinarians, farmers and pet lovers.

“And we want to build on this for the future.

“Over the past number of years, we have put in a place a clear strategy for acquisition, which has allowed us to build on our core competencies. Driving innovation is at the very heart of the Elanco business model.

“In achieving this we have been able to offer our customers new solutions to the myriad health and welfare concerns that impact on farmers and pet enthusiasts.”

She also said that the Novartis and Lohmann deals will allow Elanco’s R&D capabilities to expand significantly, from both a facilities and people point of view.

“Above all else, we are now able to tap into a much enhanced pool of research talent with a proven ability to deliver new and embracing animal health solutions. All of this is good news for practising veterinarians, livestock farmers and pet owners throughout Ireland.”

The Elanco director explained that the company is committed to finding new products and services across a wide range of veterinary disciplines.

“Our objectives for companion animals will see us address the issue of aging in pets,” she said.

“We will also seek to improve levels of animal care by minimising recovery times and reducing the pain levels associated with both acute and chronic ailments. Finding new ways to prevent disease and provide protection against parasites has always been a priority for Elanco.”